BioTuesdays

Tag - SVB Securities

Trevi Logo

SVB starts Trevi Therapeutics at OP; PT $6

SVB Securities initiated coverage of Trevi Therapeutics (NASDAQ:TRVI) with an “outperform” rating and $6 price target. The stock closed at $1.99 on Nov. 21. TRVI is a clinical-stage biopharmaceutical company developing...

Satsuma Pharmaceuticals

SVB cuts Satsuma to MP after negative SUMMIT data

SVB Securities downgraded Satsuma Pharmaceuticals (NASDAQ:STSA) to “market perform” from “outperform” and slashed its price target to $1 from $15 after the company reported negative data for the Phase 3 SUMMIT trial of...

scPharmaceuticals Logo

SVB ups scPharmaceuticals on FDA approval of Furoscix

SVB Securities upgraded scPharmaceuticals (NASDAQ:SCPH) to “outperform” from “market perform” and raised its price target to $11 from $6 after FDA approval of Furoscix for treatment of congestion in chronic heart...

SVB starts Moonlake at OP; PT $17

SVB Securities launched coverage of Moonlake Immunotherapeutics (NASDA:MLTX) with an “outperform” rating and $17 price target. The stock closed at $9.01 on Aug. 24. Moonlake is a clinical-stage biopharmaceutical company...

Pliant Therapeutics

SVB starts Pliant Therapeutics at OW: PT $33

SVB Securities initiated coverage of Pliant Therapeutics (NASDAQ:PLRX) with an “outperform” rating and price target of $33. The stock closed at $19.22 on July 19. Pliant is a clinical-stage biopharmaceutical company...

SVB Securities starts Morphic Holding at OW; PT $45

SVB Securities launched coverage of Morphic Holding (NASDAQ:MORF) with an “outperform” rating and $45 price target. The stock closed at $24.99 on July 19. Morphic is a clinical-stage biotechnology company developing...

Selecta Biosciences

SVB starts Selecta Biosciences at OP; PT $7

SVB Securities initiated coverage of Selecta Biosciences (NASDAQ:SELB) with an “outperform” rating and $7 price target. The stock closed at 88 cents on June 3. Selecta is a clinical-stage biotech company advancing its...

PepGen

SVB Securities starts PepGen at OP; PT $40

SVB Securities launched coverage of PepGen (NASDAQ:PEPG) with an “outperform” rating and $40 price target. The stock closed at $10.88 on May 27. PepGen is a clinical-stage biotech advancing its enhanced delivery...

SVB cuts Avadel Pharma PT to $6 from $18

SVB Securities slashed the price target of Avadel Pharmaceuticals (NASDAQ:AVDL) to $6 from $18, but maintained an “overweight” rating, after the FDA delayed full approval of FT-218 because of a patent issue.  Shares of...